---

---

symbols : Azn    crawled time : 01:00   

save search

---

Global Glucagon-Like Peptide 1 (GLP-1) Agonist Market Analysis Report 2024: A $133.5 Billion in 2030 Featuring Eli Lilly and Co, Pfizer, Sanofi, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk
Published: 2024-02-27 (Crawled : 01:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 4.09% | O: -1.72% H: 2.54% C: 2.54%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| -2.74% | O: -2.2% H: 2.39% C: 1.34%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -5.53% | O: -0.94% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 3.54% | O: 0.01% H: 0.79% C: 0.6%
report agonist global market

---

Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| -5.87% | O: 0.14% H: 0.0% C: -0.0%
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -3.13% | O: 0.26% H: 1.36% C: 1.36%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 6.54% | O: -0.85% H: 1.12% C: 0.43%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| -8.14% | O: 0.92% H: 0.0% C: 0.0%
UCBJY | $64.07 -4.38% 72K |

Manufacturing

| 25.87% | O: 1.46% H: 0.44% C: 0.44%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -16.01% | O: -0.27% H: 0.0% C: -1.17%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -10.79% | O: -0.2% H: 0.14% C: -0.48%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -9.24% | O: -0.06% H: 0.46% C: 0.29%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| -5.58% | O: -0.69% H: 1.42% C: 1.22%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 0.65% | O: 2.37% H: 1.51% C: 0.79%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -5.21% | O: -0.65% H: 1.63% C: 1.48%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| -7.04% | O: -0.88% H: 1.46% C: 1.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -2.16% | O: 1.67% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 4.88% | O: -2.81% H: 2.08% C: 1.38%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| -5.83% | O: -0.35% H: 1.15% C: 0.96%
lung reach cancer cell diagnostics therapy market

---

Acute Ischemic Stroke Diagnosis and Treatment Market to Reach $9.2 Billion, Globally, by 2032 at 6.1% CAGR: Allied Market Research
Published: 2023-12-14 (Crawled : 01:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K |

Communications

| -7.34% | O: -1.89% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 4.68% | O: 1.19% H: 3.09% C: 1.3%
SYK | $327.45 -2.55% 0.0% 2.1M |

Health Technology

| 12.56% | O: 0.16% H: 0.52% C: -0.64%
MDT | $79.19 0.14% 0.0% 6.1M |

Health Technology

| -3.44% | O: 1.05% H: 2.38% C: 0.81%
PHG | $19.98 -0.84% 0.0% 500K |

Health Technology

| -3.86% | O: 4.96% H: 1.5% C: 0.91%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -5.84% | O: 1.81% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M |

Health Technology

| 1.88% | O: 1.78% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 3.59% | O: 1.21% H: 0.27% C: -0.52%
stroke reach treatment research market

---

Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
Published: 2023-11-28 (Crawled : 01:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 5.08% | O: -2.8% H: 0.19% C: -0.16%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 7.23% | O: -0.72% H: 0.52% C: 0.16%
update therapeutics financial results

---

Digital Dose Inhaler Market Set for Remarkable Growth, Estimated at $104.3 Billion by 2033
Published: 2023-11-16 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 18.48% | O: 0.59% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 8.11% | O: -2.16% H: 4.44% C: 2.2%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 14.88% | O: -0.15% H: 0.23% C: 0.06%
MMM | $91.48 0.57% 0.0% 3M |

Producer Manufacturing

| -6.05% | O: -0.96% H: 0.58% C: -0.19%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 8.13% | O: 0.46% H: 0.71% C: 0.6%
set market

---

Empowering Healthcare: Global Vaccine Management System Market to Reach $441.17 million by 2028
Published: 2023-08-30 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 11.79% | O: -1.57% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -2.73% | O: 0.56% H: 0.0% C: -2.26%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -9.88% | O: -0.25% H: 0.47% C: -1.08%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -12.09% | O: 0.56% H: 0.0% C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 11.52% | O: 0.54% H: 0.27% C: -0.59%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -14.6% | O: 0.66% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -1.27% | O: 0.46% H: 0.17% C: -0.86%
management vaccine reach global system market

---

Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 11.2% | O: -1.1% H: 0.0% C: 0.0%
TAK | News | $13.16 0.08% 0.0% 1.3M |

Health Technology

| -16.61% | O: -0.95% H: 0.19% C: -0.32%
PFE A | $25.39 -0.12% -0.12% 36M |

Health Technology

| -31.09% | O: 0.19% H: 0.11% C: -1.46%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -6.46% | O: -0.01% H: 0.16% C: -0.32%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -11.53% | O: 0.03% H: 0.12% C: -0.24%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 9.18% | O: -0.91% H: 0.56% C: -0.5%
LLY | $745.95 -0.64% -0.1% 1.7M |

Health Technology

| 65.82% | O: 2.15% H: 1.18% C: 0.43%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -25.51% | O: -0.06% H: 0.46% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -4.83% | O: -0.21% H: 0.42% C: 0.13%
report business cancer treat global

---

Global Glioblastoma Multiforme (GBM) Treatment Market Report 2023: Increasing Prevalence of Brain Disorders is Expected to Propel Growth
Published: 2023-05-17 (Crawled : 01:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -10.51% | O: -1.32% H: 0.92% C: -1.34%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -9.46% | O: -0.51% H: 0.0% C: -1.05%
FUSN | $21.24 0.0% 330K |

Health Technology

| 365.79% | O: -1.54% H: 1.34% C: -2.67%
DFFN 4 | $6.6 11.68% -34.32% 350K |

Health Technology

| 14.59% | O: -0.25% H: 0.0% C: -0.78%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -9.32% | O: 0.07% H: 0.03% C: -0.84%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 17.14% | O: -0.82% H: 0.03% C: -0.44%
propel report expected treatment global growth glioblastoma market

---

Orphan drugs market to grow by USD 170.8 billion between 2022 and 2027; Growth driven by rising incidence of rare diseases - Technavio
Published: 2023-05-03 (Crawled : 01:00) - prnewswire.com
CSLLY | $87.96 3.3% 45K |

n/a

| -12.47% | O: -0.56% H: 0.36% C: -0.28%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -7.42% | O: 3.52% H: 0.0% C: 0.0%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 10.16% | O: -1.96% H: 0.0% C: 0.0%
ALPMY | $9.46 -1.11% 500K |

Manufacturing

| -38.02% | O: 1.86% H: 0.0% C: -0.65%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -10.1% | O: 0.55% H: 0.68% C: 0.33%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 8.94% | O: 1.24% H: 1.14% C: 0.11%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 8.12% | O: -0.36% H: 0.29% C: -1.2%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -13.65% | O: 0.71% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -7.37% | O: 0.75% H: 0.98% C: 0.46%
rare growth market

---

Protein Therapeutics Market size to grow by USD 153.56 billion, the availability of favorable reimbursement policies to drive the market growth - Technavio
Published: 2023-04-28 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K |

Health Technology

| -16.75% | O: -1.21% H: 0.12% C: -2.76%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -7.33% | O: -0.41% H: 0.79% C: 0.79%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -9.32% | O: -0.79% H: 0.89% C: 0.72%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 10.11% | O: -0.6% H: 2.31% C: 2.13%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -17.26% | O: -2.09% H: 0.0% C: 0.0%
BIIB | $190.55 -0.84% -0.84% 1.5M |

Health Technology

| -33.56% | O: 0.06% H: 3.94% C: 3.51%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -7.47% | O: -1.03% H: 1.02% C: 0.28%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 11.07% | O: -1.46% H: 1.39% C: 1.23%
favorable protein therapeutics growth market

---

Global Bioengineered Protein Drugs Markets Report 2023: A $521.3 Billion Market by 2027 Featuring AbbVie, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Merck and Sanofi
Published: 2023-04-20 (Crawled : 01:00) - prnewswire.com
CMXHF | $172.54 -19.21% 50 |

n/a

| -12.72% | O: -1.07% H: 1.56% C: -0.01%
CSLLY | $87.96 3.3% 45K |

n/a

| -12.73% | O: 0.23% H: 0.39% C: -0.18%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 9.19% | O: -0.08% H: 0.0% C: -0.68%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -8.44% | O: 0.42% H: 0.0% C: -0.53%
NVSEF | $93.6375 6.88% 82K |

Health Technology

| 14.66% | O: 0.61% H: 0.0% C: 0.0%
NVO | $122.75 -1.43% 0.0% 2.8M |

Health Technology

| -24.54% | O: 0.33% H: 0.36% C: -0.13%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| -5.04% | O: 0.34% H: 0.28% C: 0.25%
JNJ | News | $145.74 0.67% 0.0% 9.3M |

Health Technology

| -10.93% | O: -0.06% H: 0.86% C: 0.71%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 7.23% | O: -0.24% H: 0.0% C: -1.03%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 1.68% | O: -0.02% H: 0.37% C: 0.35%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -17.16% | O: -0.03% H: 0.0% C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K |

Health Technology

| -29.11% | O: -0.85% H: 1.51% C: 0.15%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -8.79% | O: 0.05% H: 0.11% C: -0.47%
AMGN | $262.77 -0.49% -0.49% 2M |

Health Technology

| 8.42% | O: -0.04% H: 0.11% C: -1.08%
ADMA 4 | $6.21 2.82% 2.74% 3M |

Health Technology

| 78.03% | O: -0.87% H: 1.17% C: 0.29%
report merck global protein sanofi market

---

Sleeping Aids Market size to grow by USD 36,416.19 million from 2022 to 2027, Driven by the growing patient-care services - Technavio
Published: 2023-03-28 (Crawled : 01:00) - prnewswire.com
CSLLY | $87.96 3.3% 45K |

n/a

| -8.55% | O: -1.19% H: 0.29% C: 0.06%
RYLPF | News | $20.515 3.85% 7K |

Health Technology

| 27.85% | O: 0.22% H: 0.0% C: 0.0%
GLAXF | $20.2 -14.18% 510 |

Health Technology

| 18.75% | O: 3.17% H: 0.0% C: 0.0%
AZNCF | $140.15 -4.19% 560 |

Health Technology

| -1.48% | O: 0.22% H: 0.75% C: 0.75%
GSK | $39.27 -0.83% 0.01% 2.2M |

Health Technology

| 13.01% | O: 0.26% H: 0.17% C: -0.09%
SNY | News | $45.395 -1.55% -1.58% 4.4M |

Health Technology

| -13.06% | O: 2.06% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -0.68% | O: 0.61% H: 0.07% C: -0.8%
services growing market

---

Anesthesia Drugs Market to Grow by USD 1.38 Bn, AbbVie Inc. and Baxter International Inc. Among Key Vendors - Technavio
Published: 2023-02-13 (Crawled : 01:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 620K |

n/a

| -95.56% | O: -1.11% H: 7.98% C: 2.02%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 7.63% | O: 0.39% H: 0.81% C: 0.77%
BAX | $39.65 0.33% 0.0% 2.3M |

Health Technology

| -3.05% | O: 0.12% H: 0.0% C: -1.22%
ABBV | News | $164.66 0.25% -0.15% 4.5M |

Health Technology

| 7.81% | O: -0.02% H: 1.16% C: 1.12%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| -0.89% | O: -0.51% H: 1.81% C: 1.72%
abbvie international market

---

Global Venom Based Drugs Market Research Report 2022-2023 & 2027: Increasing Use of Venom in Numerous Diseases & Technological Advancements and Rise in R&D Activities Bodes Well
Published: 2023-02-09 (Crawled : 01:00) - prnewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 5.7% | O: 6.07% H: 1.75% C: 0.35%
NVS | $92.57 -0.55% 0.0% 910K |

Health Technology

| 7.12% | O: 0.87% H: 0.17% C: -1.53%
BMY | $48.3 0.96% -0.1% 11M |

Health Technology

| -34.47% | O: -0.22% H: 0.48% C: -2.72%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 6.07% | O: 6.13% H: 0.42% C: -1.3%
research global report market

---

Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
Published: 2021-12-21 (Crawled : 01:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 23.5% | O: 3.52% H: 2.27% C: 2.27%
FBIO | $1.81 2.26% 2.21% 440K |

Health Technology

| -32.57% | O: 1.92% H: 2.26% C: -0.38%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 20.69% | O: 0.19% H: 0.94% C: 0.48%
nasdaq biotech iot

---

HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | $140.15 -4.19% 560 |

Health Technology

| 20.54% | O: -0.02% H: 1.33% C: 1.33%
HCM | $16.38 -0.43% -0.43% 190K |

Health Technology

| -51.53% | O: -4.39% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 21.17% | O: -0.07% H: 0.0% C: 0.0%
orpathys lung cancer china therapy cancer trial

---

HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
Published: 2021-09-20 (Crawled : 01:00) - globenewswire.com
HCM | $16.38 -0.43% -0.43% 190K |

Health Technology

| -56.77% | O: 1.1% H: 0.0% C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 21.53% | O: 0.0% H: 4.33% C: 4.15%
endocrine

---

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
Published: 2021-07-27 (Crawled : 01:00) - chi-med.com
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 20.21% | O: 1.58% H: 0.0% C: -0.4%
cancer trial

---

HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
Published: 2021-07-28 (Crawled : 01:00) - globenewswire.com
HCM | $16.38 -0.43% -0.43% 190K |

Health Technology

| -54.87% | O: 6.45% H: 7.99% C: 7.76%
AZN | $68.36 -0.25% -0.25% 4M |

Health Technology

| 18.8% | O: -0.75% H: 0.7% C: -0.39%
cancer trial

---

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M |

Finance

ZCMD | $2.86 108.76% 52.1% 2.3M |

Commercial Services

INVO | $1.555 104.6% 51.13% 5M |

Health Technology

ISPC | $0.437 105.16% 49.53% 37M |

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M |

OST | $0.499 21.38% 45.26% 1.9M |

XPON | News | $3.1 60.62% 37.74% 17M |

TIRX | $0.7 44.39% 30.74% 58M |

BNTC | News | $6.92 44.17% 30.64% 3.5M |

Health Technology

GGE | $0.035 19.86% 29.3% 64M |

---

Your saved searches

---